Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer.

Heliyon · 2025 · PMC11799954 · PMID 39916839

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The KATE2 study [ 23 ] showed that in the subgroup of patients with PD-L1 positive breast cancer progressed with trastuzumab, T-DM1 combined with atezolizumab showed a trend towards improving patient survival compared to T-DM1 alone.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.